Tango Therapeutics Maps 2027 Phase 3 Trial After Promising Cancer Data;Stock Down In Pre-Market

Tango Therapeutics (TNGX) fell 6.8% in pre-market trading after releasing Phase 1/2 trial results showing 82% response rate and 88% progression-free survival in pancreatic cancer patients. The decline follows a 28% stock surge ahead of the data release and coincides with broader market sell-offs. An affiliate officer's planned share sale also contributed to pressure.

Tango Therapeutics (TNGX) shares fell 6% despite positive Phase 1/2 trial data for vopimetostat and daraxonrasib in pancreatic cancer, showing an 82% response rate and 9-month progression-free survival of 88% in 22 patients. The combination was well-tolerated, with no dose-limiting toxicities. Tango plans a Phase 3 trial in 2027.

Tango Therapeutics reported an 82% response rate and 88% nine-month progression-free survival in a pancreatic cancer trial. The company plans a global trial in 2027 and will focus on PRMT5 programs, reducing its workforce by 14%. Data from other trials is expected in January 2027, according to the company.

Tango Therapeutics (TNGX) reported Phase 1/2 trial data for vopimetostat in pancreatic and lung cancer. The study showed an 82% response rate in pancreatic cancer patients, with a 9-month progression-free survival rate of 88%. The combination was well-tolerated. Tango plans a Phase 3 trial in 2027. Vopimetostat is an investigational PRMT5 inhibitor.

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy 82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% i

Tango Therapeutics reported 82% ORR in 2L/3L PDAC patients using vopimetostat + daraxonrasib, with median PFS not yet reached. The company plans a Phase 3 trial for front-line PDAC in 1H 2027, according to the press release.